ClinicalTrials.Veeva

Menu

VExUS-guided Fluid Management in Patients With Acute Kidney Injury in the Intensive Care Unit (AKIVEX)

H

Hospital de Clinicas de Porto Alegre

Status

Unknown

Conditions

Acute Kidney Injury
Critical Illness
Renal Insufficiency, Acute
Fluid Overload
Kidney; Disease, Acute
Volume Overload

Treatments

Diagnostic Test: VExUS Score

Study type

Interventional

Funder types

Other

Identifiers

NCT05240833
2021-0487

Details and patient eligibility

About

A quasi experimental study that aims to verify whether the incorporation of VExUS in patients with AKI in the Intensive Care Unit (ICU) may prompt tailored interventions to increases the number of days free from Renal Replacement Therapy (RRT) during the first 28 days.

Full description

Fluid overload is associated with organ dysfunction, such as Acute Kidney Injury (AKI), and increased mortality. It remains unclear if fluid overload is merely an epiphenomenon in critically ill patients or if organ congestion is a mediator of complications. Considering AKI related to fluid overload, diuretic therapy would reduce venous congestion and improve renal blood flow. The Venous Excess Ultrasound score (VExUS) identifies clinically significant venous congestion and indicates a high risk of post-operative AKI. This quasi-experimental study aims to verify whether the incorporation of VExUS in patients with AKI in the Intensive Care Unit (ICU) may prompt tailored interventions to increases the number of days free from Renal Replacement Therapy (RRT) during the first 28 days.

Enrollment

55 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Non-elective ICU admission
  • Severe acute kidney injury (AKI) defined either: A ≥ 2-fold increase in serum creatinine from a known pre-morbid baseline or during the current hospitalization OR Urine output < 6.0 mL/kg over the preceding 12 hours

Exclusion criteria

  • Life-threatening indication of RRT (defined as intractable hyperkalaemia, acidosis, uraemic symptoms) at Day 0
  • RRT before recruitment
  • Use of Extracorporeal membrane oxygenation (ECMO)
  • Hepatic cirrhosis or other condition with portal hypertension
  • Lack of commitment to provide RRT as part of limitation of ongoing life support
  • Known pre-hospitalization advanced chronic kidney disease, defined by an estimated glomerular filtration rate < 30 mL/min/1.73 m2 or chronic RRT
  • Refusal to sign the informed consent form

Trial design

Primary purpose

Supportive Care

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

55 participants in 1 patient group

VExUS-Guided Arm
Experimental group
Description:
VExUS results will be available for the treating physician. Patients will be treated according to current clinical practice. The use of diuretic and diuretic dosage will depend on treating physician's criteria.
Treatment:
Diagnostic Test: VExUS Score

Trial contacts and locations

1

Loading...

Central trial contact

MARCOS F RIHL, MD; MARCIO M BONIATTI, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems